Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Allogene Therapeutics (ALLO) Accumulated Depreciation & Amortization (2019 - 2025)

Allogene Therapeutics' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $9.3 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization fell 10.61% year-over-year to $9.3 million; the TTM value through Sep 2025 reached $9.3 million, down 10.61%, while the annual FY2024 figure was $13.6 million, 3.94% down from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $9.3 million at Allogene Therapeutics, up from $6.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $30.7 million in Q2 2022 and bottomed at $3.1 million in Q1 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $10.6 million (2021), against an average of $12.6 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 82.48% in 2022 before it crashed 76.73% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $10.5 million in 2021, then surged by 36.19% to $14.3 million in 2022, then decreased by 0.71% to $14.2 million in 2023, then decreased by 3.94% to $13.6 million in 2024, then crashed by 31.8% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Accumulated Depreciation & Amortization are $9.3 million (Q3 2025), $6.2 million (Q2 2025), and $3.1 million (Q1 2025).